TORONTO, March 23, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness”) (CSE: SILO), a wellness company in the psychedelic and functional mushroom markets, and Ehave, Inc. (OTC Pink: EHVVF), a provider of digital therapies for psychedelic and psychological health, today announced their intention to collaborate on a data study in coordination with some of Silo Wellness` volunteer participants. Silomentality inevitably undermines morality, especially when employees become aware of the problem and can do nothing to change it. The lack of interdepartmental communication can have a negative impact on the workflow, as information is not freely communicated across the organization. This allows some departments to work with inaccurate or outdated information. These inefficiencies and other operational inefficiencies due to silos also complicate the way companies add value to customers and affect profitability. “This study is conducted with EEG devices to measure brain activity before, during and after the administration of psilocybin and its derivatives. To perform the test, we put a comfortable cap on the individual`s head. The cap contains sensors that measure brain waves of different frequencies. This is a non-invasive reading of brain activity and frequency patterns,” said Alfred Farrington II, Chief Information Officer of Ehave. In addition to developing and facilitating the psilocybin-supported wellness retirement agenda, Silo Wellness will be responsible for acquiring retirement sites for the Brain Mapping study in Jamaica.
Silo Wellness will also be responsible for facilitating the administration of psilocybin and its derivatives in natural variants. Silo Pharma is a biopharmaceutical company that focuses on merging traditional therapeutic drugs with psychedelic research for people with indications such as depression, PTSD, Parkinson`s disease and other rare neurological diseases. Silo`s mission is to identify assets to license and fund research that we believe will transform for the well-being of patients and the healthcare industry. For more information, see www.silopharma.com. “Silo Wellness is pleased to collaborate on innovative methods to enable wellness retreat participants to have the best experience through psychoactivity screening, which will allow us to learn more about the therapeutic dosage of psilocybin products,” said Douglas K. Gordon, Chief Executive Officer of Silo Wellness. “Scientific approaches like this are consistent with our ongoing commitment to technology, applications and formats such as our patented psilocybin nasal spray to destigmatize and transform the psychedelic landscape.” Ehave CEO Ben Kaplan said, “Brain mapping shows which parts of the brain are not functioning as they should and how these areas are influenced by external factors.” Lord.